Lynparza secures long-term survival evidence in ovarian cancer

Has secured clinical evidence for improving overall survival in BRCA·HRD patients

Despite inclusion in standard global guidelines, reimbursement status for HRD-positive patients remains delayed

PARP inhibitor 'Lynparza (olaparib)' 

The evaluation criteria for first-line maintenance therapy in ovarian cancer is shifting.

Delaying disease recurrence, progression-free survival (PFS), and overall survival (OS) improvements are now included as primary endpoints for assessing therapeutic efficacy, underscoring the growing importance of initiating early-stage treatment strategies optimized for long-term prognosis.

According to biopharmaceutical industry sources, recent global clinical guidelines are increasingly prioritizing biomarker-based personalized medicine for the ovarian cancer therapy.

As treatment strategies become increasingly subdivided, targeting patients with BRCA mutations to those with homologous recombination deficiency (HRD), the clinical value of first-line maintenance therapies backed by long-term survival data has increased. Consequently, the therapeutic strategy is shifting toward subdividing treatment pathways based on patient-specific biomarker profiles to maximize the likelihood of modifying long-term prognosis from the initial maintenance therapy.  

Amid these clinical shifts, the PARP inhibitor 'Lynparza (olaparib)' is being assessed as a therapeutic option with long-term follow-up data across both BRCA-mutated and HRD-positive patients from the SOLO-1 and PAOLA-1 trials, respectively.

Ovarian cancer has the highest mortality rate among all gynecological malignancies. A significant majority of patients are diagnosed at an advanced stage. Despite high initial response rates to frontline interventions, the clinical course is characterized by frequent recurrences, followed by sequential rounds of subsequent lines of therapy. Given these clinical challenges, real-world oncology practice is rapidly shifting toward maintenance strategies that prioritize overall survival (OS) outcomes alongside progression-free survival.  

The SOLO-1 study has proved Lynparza's effectiveness as a first-line maintenance therapy for BRCA-mutated ovarian cancer. At the 3-year follow-up analysis, the progression-free survival rate was 60% in the Lynparza group, compared with 27% in the placebo arm, demonstrating a 70% reduction in the risk of disease progression or death. 

Subsequent 7-year follow-up data provided evidence of long-term survival. The overall survival rate in the Lynparza group was confirmed at 67%, a 45% reduction in the risk of death compared to the placebo control (mOS: NR vs. 75.2 months). This indicates that 2 of 3 patients survived to the 7-year mark, validating that the survival benefit of frontline Lynparza maintenance therapy is sustained over extended follow-up.  

In addition to the BRCA-positive patients, Lynparza demonstrated a consistent overall survival benefit in patients with HRD-positive status.

In the 5-year follow-up analysis of the PAOLA-1 clinical trial, the 5-year overall survival rate among HRD-positive patients was 65.5% in the Lynparza + bevacizumab combination therapy group versus 48.4% in the bevacizumab monotherapy group, translating to a 38% reduction in the risk of death.  

Within the same analysis, the median progression-free survival reached 46.8 months and 17.6 months, respectively, representing a 59% reduction in the risk of disease progression or death.  

The significance of the PAOLA-1 5-year data extends beyond merely securing additional long-term tracking points. Demonstrating a statistically significant overall survival benefit in the first-line maintenance setting is difficult in ovarian cancer clinical trials, as the data are highly susceptible to confounding by multiple sequential lines of subsequent therapies administered after recurrence.  

This trial demonstrated that the Lynparza + bevacizumab combination therapy maintains a highly consistent clinical benefit for HRD-positive patients over an extended long-term follow-up period, consistent with the efficacy seen in the initial primary analyses.

Notably, the long-term follow-up study results of sustained PFS, alongside enhanced 5-year survival rates and reduced mortality risk, provides significant evidence supporting the clinical value proposition of this therapeutic strategy. This outcome confirms that frontline maintenance product selection directly correlates with downstream long-term prognostic outcomes.  

Homologous recombination deficiency represents a critical biomarker detected in approximately half of all patients with high-grade serous ovarian cancer, the primary histological subtype of the disease. As the ovarian cancer treatment paradigm transitions into biomarker-based precision oncology, the clinical weight of mature long-term survival evidence generated within the HRD-positive population has risen substantially.

This clinical evidence is firmly reflected in international therapeutic standards. The National Comprehensive Cancer Network (NCCN) Guidelines recommend Lynparza following platinum-based chemotherapy in both BRCA-mutated and HRD-positive cohorts. Notably, within the HRD-positive population, the Lynparza plus bevacizumab combination therapy is the only PARP inhibitor-based therapy designated as a Category 1 recommendation.

Despite strong clinical evidence and inclusion in standard global guidelines, patient market access bottlenecks persist in South Korea. While health insurance coverage is active for the BRCA-mutated cohort, the Lynparza-bevacizumab combination based on the PAOLA-1 trial for HRD-positive patients remains non-reimbursed. Although the therapy cleared the initial regulatory hurdle at the Cancer Disease Review Committee (CDRC) in September of last year, final implementation of the expanded reimbursement criteria has been delayed for nearly a year.  

Consequently, oncologists emphasize that even when companion diagnostic HRD screening identifies patients who would derive clinical benefit, financial barriers prevent the deployment of this optimized first-line maintenance strategy in real-world clinical practice.

Discussions about the need to expand reimbursement for Lynparza have intensified recently. "The 2nd National Health Insurance Comprehensive Plan," finalized in March, includes provisions to review expanded reimbursement criteria for oncology therapeutics utilized in ovarian cancer care. Simultaneously, calls for improving patient access continue to gain traction across regulatory policy forums and academic symposia.  

Professor Se Ik Kim of the Department of Obstetrics and Gynecology at Seoul National University Hospital said, "Given that ovarian cancer carries a high recurrence rate requiring repetitive lines of sequential therapy, it is imperative to establish frontline strategies focused on maximizing long-term survival probability from the outset. Rather than simply delaying time-to-recurrence, clinical management must increasingly prioritize therapeutic strategies that optimize long-term prognosis by integrating patient-specific biomarker characteristics."

Professor Kim added that Lynparza is a PARP inhibitor with mature, long-term survival data across both BRCA-mutated and HRD-positive populations from the SOLO-1 and PAOLA-1 trials. He emphasized that it is highly clinically meaningful because it demonstrates that frontline maintenance product selection in the HRD-positive population can significantly dictate downstream, long-term therapeutic outcomes. 

Professor Kim concluded by emphasizing that "While clinicians can now screen and identify patients expected to benefit clinically via companion HRD testing, patient access to treatment remains restricted. We expect that discussions on patient access advance rapidly so that clinically validated therapeutic strategies can be applied to real-world patient care. "